Stay updated on GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The page revision was updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-07T09:07:29.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision updated from v3.4.1 to v3.4.2 with no changes to the study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-14T02:15:45.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1 on the Study Details page.
    Difference
    0.1%
    Check dated 2026-02-06T17:37:38.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    Minor UI and labeling updates were made to the page, including the glossary toggle labels (Show glossary / Hide glossary) and new text such as "Last Update Submitted that Met QC Criteria", "No FEAR Act Data", and "Revision: v3.4.0", while the older phrasing "Last Update Submitted that met QC Criteria", "No FEAR Act data", and "Revision: v3.3.4" were removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-01-23T10:11:04.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    The page shows a minor revision history update: added Revision: v3.3.4 and removed Revision: v3.3.3. This change does not affect study details or user actions; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-16T06:44:29.000Z thumbnail image
  8. Check
    85 days ago
    Change Detected
    Summary
    Added a Locations section with California, Colorado, Florida, Illinois, Kentucky, Louisiana, New Hampshire, and Virginia; removed HHS Vulnerability Disclosure and the listed state location sections, and updated the revision to v3.3.3.
    Difference
    1.0%
    Check dated 2025-12-24T15:19:29.000Z thumbnail image

Stay in the know with updates to GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.